门诊使用口服降糖药血糖控制不佳的2型糖尿病患者转换为德谷胰岛素利拉鲁肽注射液的案例分享  

Case Sharing of Insulin Degludec and Liraglutide Injection in Type 2 Diabetic Patients Poorly Controlled by Oral Antidiabetic Drugs in Outpatient

作　　者：何冰[1] 余学锋 HE Bing;YU Xuefeng(Shengjing Hospital of China Medical University,Shenyang Liaoning 110004,China;Tongji Hospital,Tongji Medical College Huazhong University of Science&Technology,Wuhan Hubei 430030,China.)

机构地区：[1]中国医科大学附属盛京医院,辽宁沈阳110004 [2]华中科技大学同济医学院附属同济医院,湖北武汉430030

出　　处：《药品评价》2022年第14期873-876,共4页Drug Evaluation

摘　　要：回顾性总结3例门诊口服降糖药控制不佳转换为德谷胰岛素利拉鲁肽注射液联合二甲双胍和(或)钠?葡萄糖共转运蛋白2抑制剂(sodium?glucose cotransporter 2 inhibitor,SGLT2i)的成人2型糖尿病(type 2 diabetes mellitus,T2DM)患者病例资料,随访发现,治疗1~2周后所有患者空腹和餐后血糖均有明显改善,2例患者体重、腰围有一定程度的下降,均无低血糖反应和胃肠道不良反应发生,临床有效性和耐受性良好。Retrospective analyze clinical data of 3 adult type 2 diabetic patients,who were converted to insulin degludec and liraglutide injection combined metformin with or without SGLT2 inhibitor due to uncontrolled by oral antidiabetic drugs in outpatient.After 1~2 weeks,both fasting and postprandial glucose improved all of the patients.Body weight loss and abdominal circumference loss were seen in 2 patients,that no hypoglycemia and gastrointestinal adverse events.In general,insulin degludec and liraglutide injection was effective and well-tolerated.

关 键 词：糖尿病 2型 德谷胰岛素利拉鲁肽注射液 口服降糖药 门诊 

分 类 号：R587.1[医药卫生—内分泌]